Idelalisib—targeting PI3Kδ in patients with B-cell malignancies View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-03-18

AUTHORS

Jan A. Burger, Klaus Okkenhaug

ABSTRACT

Idelalisib, the first PI3Kδ inhibitor in clinical use, has excellent activity in patients with chronic lymphocytic leukaemia and indolent B-cell lymphomas, heralding a new era of targeted therapy for these types of cancer. Idelalisib intercepts critical communications between B cells and the microenvironment, including B-cell receptor signalling and chemokine networks.

PAGES

184-186

References to SciGraph publications

  • 2014-01-31. PI3K and cancer: lessons, challenges and opportunities in NATURE REVIEWS DRUG DISCOVERY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/nrclinonc.2014.42

    DOI

    http://dx.doi.org/10.1038/nrclinonc.2014.42

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1046642642

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/24642682


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "B-Lymphocytes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Chemokine CCL3", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Class I Phosphatidylinositol 3-Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Clinical Trials as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Diarrhea", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Leukemia, Lymphocytic, Chronic, B-Cell", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lymphoma, B-Cell", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Molecular Targeted Therapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mutation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Phosphatidylinositol 3-Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Phosphoinositide-3 Kinase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Kinase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Purines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Quinazolinones", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Signal Transduction", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Microenvironment", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.240145.6", 
              "name": [
                "Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Burger", 
            "givenName": "Jan A.", 
            "id": "sg:person.01327752473.62", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327752473.62"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Laboratory of Lymphocyte Signalling and Development, The Babraham Institute, CB22 3AT, Cambridge, UK", 
              "id": "http://www.grid.ac/institutes/grid.418195.0", 
              "name": [
                "Laboratory of Lymphocyte Signalling and Development, The Babraham Institute, CB22 3AT, Cambridge, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Okkenhaug", 
            "givenName": "Klaus", 
            "id": "sg:person.01356616513.06", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356616513.06"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nrd4204", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035315734", 
              "https://doi.org/10.1038/nrd4204"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2014-03-18", 
        "datePublishedReg": "2014-03-18", 
        "description": "Idelalisib, the first PI3K\u03b4 inhibitor in clinical use, has excellent activity in patients with chronic lymphocytic leukaemia and indolent B-cell lymphomas, heralding a new era of targeted therapy for these types of cancer. Idelalisib intercepts critical communications between B cells and the microenvironment, including B-cell receptor signalling and chemokine networks.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/nrclinonc.2014.42", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.3635849", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2784635", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2438826", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1034153", 
            "issn": [
              "1759-4774", 
              "1759-4782"
            ], 
            "name": "Nature Reviews Clinical Oncology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "4", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "11"
          }
        ], 
        "keywords": [
          "chronic lymphocytic leukemia", 
          "types of cancer", 
          "cell receptor signaling", 
          "indolent B", 
          "chemokine network", 
          "cell lymphoma", 
          "lymphocytic leukemia", 
          "cell malignancies", 
          "clinical use", 
          "receptor signaling", 
          "PI3K\u03b4 inhibitors", 
          "patients", 
          "idelalisib", 
          "lymphoma", 
          "malignancy", 
          "therapy", 
          "leukemia", 
          "cancer", 
          "PI3K\u03b4", 
          "inhibitors", 
          "microenvironment", 
          "signaling", 
          "cells", 
          "new era", 
          "excellent activity", 
          "activity", 
          "use", 
          "types", 
          "era", 
          "communication", 
          "network", 
          "critical communication", 
          "first PI3K\u03b4 inhibitor", 
          "Idelalisib intercepts critical communications", 
          "intercepts critical communications"
        ], 
        "name": "Idelalisib\u2014targeting PI3K\u03b4 in patients with B-cell malignancies", 
        "pagination": "184-186", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1046642642"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/nrclinonc.2014.42"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "24642682"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/nrclinonc.2014.42", 
          "https://app.dimensions.ai/details/publication/pub.1046642642"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-11-01T18:22", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_636.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/nrclinonc.2014.42"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2014.42'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2014.42'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2014.42'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2014.42'


     

    This table displays all metadata directly associated to this object as RDF triples.

    204 TRIPLES      21 PREDICATES      83 URIs      74 LITERALS      29 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/nrclinonc.2014.42 schema:about N098151d2f88e4287a5e85b86a26185ee
    2 N312402ec5955476a907d4fa5ae2a01f9
    3 N36fb5889596242ca832f1f60ec342bd1
    4 N48b48219d11146f186a51212fe131f63
    5 N572abe68d50143818caa157a9016b67a
    6 N59186ebaa08b4a61b7cbc64568b9e5db
    7 N6dd55ebda9a8414ab9589dbfbb9a48a2
    8 N785b796297b84680abe35888cfaa1ea7
    9 N8859e257a63f4119b4f78f697c23d732
    10 N929e06cb7ed542c88940b55f677211fd
    11 N9c4725c3e31e4364a52fbe69c7592da4
    12 Na2a62a8c8cfe4ccea9bc78e4c44feeca
    13 Nac96f09ace6f4acb842707a78d46272e
    14 Nb155414f81624578b1dd4493620eb361
    15 Nb69939f1c4544a10a31cb1800f7515ce
    16 Nbd4c617380874a68a25a71321909b548
    17 Nc2d6916266a04121801af4bf2ee019c1
    18 Nc7d5ece5cab6465b98aa39fc04c87d32
    19 Nd4f0749a3edd4a6598ee7a9ae46d1067
    20 Nd70f2a8292a04ab28291f5924ced5a4f
    21 Ndf6b289275ba47e382cf4763cc71d833
    22 Ne49a0632509f4727a50ee7354ce07f3a
    23 anzsrc-for:11
    24 anzsrc-for:1112
    25 schema:author Ne3c5ee8a32de49708f2c56a4128f3095
    26 schema:citation sg:pub.10.1038/nrd4204
    27 schema:datePublished 2014-03-18
    28 schema:datePublishedReg 2014-03-18
    29 schema:description Idelalisib, the first PI3Kδ inhibitor in clinical use, has excellent activity in patients with chronic lymphocytic leukaemia and indolent B-cell lymphomas, heralding a new era of targeted therapy for these types of cancer. Idelalisib intercepts critical communications between B cells and the microenvironment, including B-cell receptor signalling and chemokine networks.
    30 schema:genre article
    31 schema:isAccessibleForFree true
    32 schema:isPartOf N6b35240e808e43eb9775212622c670d9
    33 Ne5f99a905add42eb99728e8365c89476
    34 sg:journal.1034153
    35 schema:keywords Idelalisib intercepts critical communications
    36 PI3Kδ
    37 PI3Kδ inhibitors
    38 activity
    39 cancer
    40 cell lymphoma
    41 cell malignancies
    42 cell receptor signaling
    43 cells
    44 chemokine network
    45 chronic lymphocytic leukemia
    46 clinical use
    47 communication
    48 critical communication
    49 era
    50 excellent activity
    51 first PI3Kδ inhibitor
    52 idelalisib
    53 indolent B
    54 inhibitors
    55 intercepts critical communications
    56 leukemia
    57 lymphocytic leukemia
    58 lymphoma
    59 malignancy
    60 microenvironment
    61 network
    62 new era
    63 patients
    64 receptor signaling
    65 signaling
    66 therapy
    67 types
    68 types of cancer
    69 use
    70 schema:name Idelalisib—targeting PI3Kδ in patients with B-cell malignancies
    71 schema:pagination 184-186
    72 schema:productId N3a322b4b389243fa94f18e58afa7fbcd
    73 N95192a93b92a48359fd35c7d512c1edb
    74 Ncd5758cd0ca8441ca713e753dba6b3c3
    75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046642642
    76 https://doi.org/10.1038/nrclinonc.2014.42
    77 schema:sdDatePublished 2021-11-01T18:22
    78 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    79 schema:sdPublisher Nb844b7260aa6465598e99bdbd4a0e452
    80 schema:url https://doi.org/10.1038/nrclinonc.2014.42
    81 sgo:license sg:explorer/license/
    82 sgo:sdDataset articles
    83 rdf:type schema:ScholarlyArticle
    84 N098151d2f88e4287a5e85b86a26185ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    85 schema:name Chemokine CCL3
    86 rdf:type schema:DefinedTerm
    87 N312402ec5955476a907d4fa5ae2a01f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    88 schema:name Class I Phosphatidylinositol 3-Kinases
    89 rdf:type schema:DefinedTerm
    90 N36fb5889596242ca832f1f60ec342bd1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    91 schema:name Protein Kinase Inhibitors
    92 rdf:type schema:DefinedTerm
    93 N3a322b4b389243fa94f18e58afa7fbcd schema:name dimensions_id
    94 schema:value pub.1046642642
    95 rdf:type schema:PropertyValue
    96 N48b48219d11146f186a51212fe131f63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    97 schema:name Mice
    98 rdf:type schema:DefinedTerm
    99 N572abe68d50143818caa157a9016b67a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    100 schema:name Treatment Outcome
    101 rdf:type schema:DefinedTerm
    102 N59186ebaa08b4a61b7cbc64568b9e5db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    103 schema:name Quinazolinones
    104 rdf:type schema:DefinedTerm
    105 N6b35240e808e43eb9775212622c670d9 schema:issueNumber 4
    106 rdf:type schema:PublicationIssue
    107 N6dd55ebda9a8414ab9589dbfbb9a48a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    108 schema:name Mutation
    109 rdf:type schema:DefinedTerm
    110 N785b796297b84680abe35888cfaa1ea7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    111 schema:name Clinical Trials as Topic
    112 rdf:type schema:DefinedTerm
    113 N8859e257a63f4119b4f78f697c23d732 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    114 schema:name Phosphatidylinositol 3-Kinases
    115 rdf:type schema:DefinedTerm
    116 N929e06cb7ed542c88940b55f677211fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Lymphoma, B-Cell
    118 rdf:type schema:DefinedTerm
    119 N95192a93b92a48359fd35c7d512c1edb schema:name doi
    120 schema:value 10.1038/nrclinonc.2014.42
    121 rdf:type schema:PropertyValue
    122 N9c4725c3e31e4364a52fbe69c7592da4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Purines
    124 rdf:type schema:DefinedTerm
    125 Na2a62a8c8cfe4ccea9bc78e4c44feeca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Phosphoinositide-3 Kinase Inhibitors
    127 rdf:type schema:DefinedTerm
    128 Nac96f09ace6f4acb842707a78d46272e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Molecular Targeted Therapy
    130 rdf:type schema:DefinedTerm
    131 Nb155414f81624578b1dd4493620eb361 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Diarrhea
    133 rdf:type schema:DefinedTerm
    134 Nb69939f1c4544a10a31cb1800f7515ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    135 schema:name Signal Transduction
    136 rdf:type schema:DefinedTerm
    137 Nb844b7260aa6465598e99bdbd4a0e452 schema:name Springer Nature - SN SciGraph project
    138 rdf:type schema:Organization
    139 Nbd4c617380874a68a25a71321909b548 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Animals
    141 rdf:type schema:DefinedTerm
    142 Nc2d6916266a04121801af4bf2ee019c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Leukemia, Lymphocytic, Chronic, B-Cell
    144 rdf:type schema:DefinedTerm
    145 Nc7d5ece5cab6465b98aa39fc04c87d32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name Tumor Microenvironment
    147 rdf:type schema:DefinedTerm
    148 Ncd5758cd0ca8441ca713e753dba6b3c3 schema:name pubmed_id
    149 schema:value 24642682
    150 rdf:type schema:PropertyValue
    151 Nd4f0749a3edd4a6598ee7a9ae46d1067 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    152 schema:name Humans
    153 rdf:type schema:DefinedTerm
    154 Nd70f2a8292a04ab28291f5924ced5a4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    155 schema:name Antineoplastic Agents
    156 rdf:type schema:DefinedTerm
    157 Ndf6b289275ba47e382cf4763cc71d833 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Neoplasm Proteins
    159 rdf:type schema:DefinedTerm
    160 Ne3c5ee8a32de49708f2c56a4128f3095 rdf:first sg:person.01327752473.62
    161 rdf:rest Nfa51a22a38fc46d0986a5d9da867b892
    162 Ne49a0632509f4727a50ee7354ce07f3a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name B-Lymphocytes
    164 rdf:type schema:DefinedTerm
    165 Ne5f99a905add42eb99728e8365c89476 schema:volumeNumber 11
    166 rdf:type schema:PublicationVolume
    167 Nfa51a22a38fc46d0986a5d9da867b892 rdf:first sg:person.01356616513.06
    168 rdf:rest rdf:nil
    169 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    170 schema:name Medical and Health Sciences
    171 rdf:type schema:DefinedTerm
    172 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    173 schema:name Oncology and Carcinogenesis
    174 rdf:type schema:DefinedTerm
    175 sg:grant.2438826 http://pending.schema.org/fundedItem sg:pub.10.1038/nrclinonc.2014.42
    176 rdf:type schema:MonetaryGrant
    177 sg:grant.2784635 http://pending.schema.org/fundedItem sg:pub.10.1038/nrclinonc.2014.42
    178 rdf:type schema:MonetaryGrant
    179 sg:grant.3635849 http://pending.schema.org/fundedItem sg:pub.10.1038/nrclinonc.2014.42
    180 rdf:type schema:MonetaryGrant
    181 sg:journal.1034153 schema:issn 1759-4774
    182 1759-4782
    183 schema:name Nature Reviews Clinical Oncology
    184 schema:publisher Springer Nature
    185 rdf:type schema:Periodical
    186 sg:person.01327752473.62 schema:affiliation grid-institutes:grid.240145.6
    187 schema:familyName Burger
    188 schema:givenName Jan A.
    189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327752473.62
    190 rdf:type schema:Person
    191 sg:person.01356616513.06 schema:affiliation grid-institutes:grid.418195.0
    192 schema:familyName Okkenhaug
    193 schema:givenName Klaus
    194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356616513.06
    195 rdf:type schema:Person
    196 sg:pub.10.1038/nrd4204 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035315734
    197 https://doi.org/10.1038/nrd4204
    198 rdf:type schema:CreativeWork
    199 grid-institutes:grid.240145.6 schema:alternateName Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, TX, USA
    200 schema:name Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, TX, USA
    201 rdf:type schema:Organization
    202 grid-institutes:grid.418195.0 schema:alternateName Laboratory of Lymphocyte Signalling and Development, The Babraham Institute, CB22 3AT, Cambridge, UK
    203 schema:name Laboratory of Lymphocyte Signalling and Development, The Babraham Institute, CB22 3AT, Cambridge, UK
    204 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...